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A recent treatment review
in the Division of
Radiation Oncology
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mpraglottic larynx, parotid
gland, lung, and tonsils.
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Radiation Oncology:
Targeting Effective Treatment
by Beth W. Allen

he questions fly from all quarters of the room:
"What '.s the performance status ? 1Vhat '.s the risk of
pneumonitis? Did the surgery help? vVhat were the
surgical margins ? H ow does the protocol accou nt
for lung motion ? vVhat 's the morbidity ?

This scene, charged with the vitality of a public meetin g
and the intensity of courtroom testimony, plays out four
days a week in the M. D. Anderson Cancer Center Division
of Radiation Oncology.
(Continued on page 2)

Radiation Oncology
( Continued from page 1)

Sta nding before division colleagues, physicians pr nt cases
under their care and their plans
for urativ tr atment. With this
m thod, patients get not only a
second opinion but also a third,
fourth and a fifth-mak that a 25th .
"Every new pot ntially curable
pati nt i r vi wed by a roomful
of physicians, staff, residents, and
train ee -on the averag , 25 physicians-who review ev ry ca ," aid
Divi ion of Radi ation Oncology
head j ame D. Cox, M.D.
Meeting four morning every
week, the physicians learn a h
pati n t's ba ic heal th tati tic , th
hi t ry of diagnosi along with the
presenting sym ptoms and signs,
the histology and pathology reports,
p rtin nt positiv finding , d i as
tag , oth r treatment, and radiotherapy plan . Then the questions
start.
Th u th d ivi ion practic what
i its 30-year treatment-d finin g
and -refining process: patients are

ass
d, treated, evaluated; outcomes analyzed ; and treatment
r vi d to improv outcomes.
'This has b n ongoing for more
than three de ad -, 'says Dr. ox.
" obody el d
it- every morning, fo ur day aw k. It' totally
uniq ue." Dr. ox redits th pro ess
with en uring evolution of th be t
tr atm nt because it i ba ed on
outcome of the more than 3,000
patients treated in the division
annually.
To Dr. Cox, providing excellent
treatment m an paying attention
to what you do n't want to do--cau e
harm to normal tis ues-a well a
what you do want to do-eli minate
or reduce cancer. sing the latest
dose-response data, selectively
employing chemotherapy as an
adjuvant th rapy, and implem nting
th re -dim n i nal conformal radiation th rapy make it po ible for
physicians in the division to reduce
radiation volume. The division's
efforts to protect normal structure
fro m radiation al o involv t hnology advanc m nt.

Th division' creation-a miniature multi] af c llimator- is h !ping
physician mor carefully define
treatment fi Id . The collimator, for
which th division i s king a patent,
permits very precise application of
compucer-assi ted tr atment planning and three-dimensional conformal radiation th rapy (3-D CRT).
tissue- paring advance over conv n ti nal radioth rapy, 3-D CRT
i a ociat d wi th fewer sid ffi cts
and I s po tth rapy morbidity. Dr.
Cox points to th is work as an example
of the division 's ability to create
new application from technical
advances.
Anoth rte hnicaJ development,
prung from lab ratory work with
fibrobla t cultures, is genetic te ting
to identify patients with ultra nsitivity to radiation.
·
"Although th i ultras n itivity is
rare, 3%-5% of p pl treated with
high dos
xhi bit it," according to
Dr. Cox, who says such ultrasen itivity
can produce more severe scarring
than normal and long-term con equences in treatment areas, such

- - - - PROTOCOLS - - - -

Radiotherapy
Protocols Offer
Treatment for
Range of Sites
and 'Types of Cancer
The following list is only a sample of the
rad iotherapy protocols open to patients
with many types and stages of cancer.
Contact the New Patient Referral Office or
the M. D. Anderson clinical trials listing on
the World Wide Web (see nu mbers and
addresses below) for more information.
• Extended-field radiation therapy for
favo rable Hodgkin's disease (I D95-162).
Physician: James D. Cox, M.D.
Patients who are 16 years of age but
less than 50 who have a histologic
diagnosis of stage IA or IIA Hodgkin's
disease with a mediastinal-to-thoracic
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ratio of <0.35 are eli9 ible fo r participation in this study of treatment. Patients
must have no more than three regions of
involvement if the disease is supradiaph ragmatic. Prior chemotherapy or
radiotherapy makes a patient ineligible,
and patients will not have chemotherapy
or immunotherapy with the radiotherapy.
The platelet count must be >175,000/
mm 3 and the absolute granulocyte count
>2,800/mm 3•
• Aphase 1/11 trial to evaluate brachytherapy as the sole method of rad iation
therapy for stage I and 11 breast carcinoma (RTOG95-17). Physician: Eric
Strom, M.D.
"Usually I see candidates for this
feasi bility study before definitive surgical
manageme nt," said principal investigator Dr. Eric Strom, associate professor
of rad iation oncology. This helps ensure
that patients' surgical treatment meets
specific requirements in this brachy-

therapy regimen open to patients with
American Joint Committee on Cancer
stage I or 11 breast cancer (T1 NO, T2N0,
T1 N1, or T2N1 ). Disease must be
confi rmed by histology, and the lesion ,
which must be~ centimeters, must be
confi rmed by pathology. "The margins
of resection must be clear, and an
extensive intraductal component must
not be present," he said. Treatment must
have been tylectomy with axillary
dissection, which must have included
sampling at least six nodes and fi nd ing
fewer than four positive. Dr. Strom said
that at least six clips must be used to
mark the tylectomy cavity. Absence of
microcalcifications must be proved by
mam mog raphy after surgery if they
were present before surgery. Patients
with distant metastases or a diagnosis
of invasive in situ lobular carcinoma,
ductal carcinoma in situ, or nonepithelial
breast malignancy (sarcoma or lymphoma) are ineligible.

Dr. James D. Cox (front row) listens
to comments f rom Dr. Ritsuko Komaki
(second from left on second row) in a
Division of Radiation Oncology morning

review session. left to right on second
row are Dr. Moshe Maor, Dr. Komaki,
Dr. Tahir ljaz, and Dr. Scott Lankford.

gastrointestinal tract, genitourinary
tract, head and neck, or skin; gynecologic, pediatric, or thoracic cancers;
or lympho ma or sarcoma.
"The experience of a faculty
member with a specific disease is
vastly greater than would be expected
anywhere else," says Dr. Cox. H e
as skin, subcutaneous tissues,
bones, an d nerves.
All paLiems with breast cancer
undergo this testing, as do patients in
whom a reaction has occurred in

add five years to the 35-year research
endeavor.
Dr. Cox said there m ay be on ly
one other radiation oncology division
in the country that treats as many

trea tment and oth ers suspected of
grea te r susceptibility to injury.
T he resea rc h p rogram also
encompasses o ne of the longestru nning federa l gran ts in rad iotherapy in the Un ited States. A
recently app roved renewal will

patients. Hig h p atient volume means
rad iation o nco logists accumula te
broad experience within a specialty
or subspecialty. Physicia ns within the
divisio n specialize in treati ng o ne or
two of tl1e following can cers: cancer
of the breast, central nervous system,

----4-

• Phase Ill intergroup randomized
comparison of radiation alone vs.
preradiation chemotherapy for pure and
mixed oligodendrogliomas (RTOG9402). Physician: W K. Alfred Yung, M.D.
'The incidence of oligodenctroglioma
appears to be increasing," said Dr. W. K.
Alfred Yung, professor and deputy
chairman of the Department of NeuroOncology and principal investigator of
this phase Ill study. For that reason,
Dr. Yung said, "It is important to
establish the role of chemotherapy in
the treatment of this tumor." Eligible
are patients 18 years or older whose
unifocal or multifocal supratentorial pure
or mixed oligodendrogliomas have been
confirmed by pathology and are not
predominantly located in the posterior
fossa. Patients should not have had
radiotherapy or chemotherapy previously. Karnofsky performance status
should ~ 60. Required blood counts are
as follows: platelet counts ~150,000/

estimates tha t each radiaLio n oncologist a t M. D. Anderson sees as m any
patie nts within his or he r spe cia lty as
other radiation oncologists see across
th e spectrum of dive rse cancers in
an y give n year. As Dr. Cox e xpla ins,
this e xperie nce provides "tremendous sp ecialization expertise a nd
technical experience with all kinds
of variations."
Of the patien ts who come to M. D.
Anderson for radio therapy, a bo ut
(Contin1ted on page 4 )
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mm3; absolute granulocyte count
21,500/mm3; a serum creatinine count
$1.5 times normal; and bilirubin, serum
aspartate aminotransferase, and alkaline
phosphatase values s2 times normal.
• Stereotactic fractionated radiotherapy
using a mini multileaf collimator and a
relocatable frame for brain tumors
(ID97-011). Physician: Moshe Maor,
M.O.
Patients older than 16 years with a
recurrent primary brain tumor or new
and recurrent brain metastasis well
defined by magnetic resonance imaging
are eligible for this study. They must
have a Zubrod performance status
of 22 and a life expectancy of three
months. Any primary or metastatic
tumors outside the brain must be stable.
• A randomized phase II trial of concurrent radiation and chemotherapy for
advanced squamous cell carcinoma of
the head and neck (RTOG97-03).

Physician: Adam Garden, M.D.
To be included in this study, patients
must be 18 years or older and have
histologically proved squamous cell
carcinoma of the oral cavity, oropharynx,
or hypopharynx (stage Ill or IV), without
metastasis. Life expectancy must be ~6
months, and Karnofsky performance
status must be ~70. Metastatic disease
at a distant site or clinically significant
heart disease makes patients ineligible
for participation.
FoR MORE INFORMATION

about these clinical

trial~, physicians or patients should call
the M. D. Anderson Inf ormation Line.

Those within the United States, please
call (800) 392-1611; those in Houston
or outside the United States, pl.ease call
(713) 792-6161. Visit the M. D. Anderson Cancer Center clinical trials Web site
al http://www.clinicaltrials.org for a
more complete listing of treatment research
protocols and inclusion and exclusi-0n
critmia.
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(TALK BACK).for the Last Time
~ Interest Survey Concludes in This Issue

Radiation Oncology

This is your last opportunity to complete this interest survey. Please fill out the survey
if you haven't before. Return it to Oncolog Survey, Scientific Publications-234, M. D.
Anderson cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030. Or fax it to
(71 3) 794-1370. In thanks, we'll send you a copy of the award-winning M. D. Anderson's
Road Mop to Cancer Prevention.

•
,.
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Rank the following withineach column (1 = Most important}.
_ Brevity of articles
_ Relevance to general practice
_ Understanding oncology
llmellness of articles _ Relevance to patient
practice in general
_ Depth of reporting
_ Relevance to practice at Anderson _ Understanding
Anderson's approach
to treatment

-

■

Check one of the options to complete the following sentences.

I O do
O do not currently read OncoLog.
I O do
O do not
think that pharmaceutical sponsorship diminishes a newsletter's authority.
I O would O would not be willing to pay for a subscription to OncoLog.
■

Complete the following sentences by filling in the blank.

The cancer-related topic I am most interested in is _ _ _ _ _ _ __ _ _ _ _ __
My favorite periodical for cancer information
■

is _ _ _ _ _ _ __ _ _ _ _ __ _

(Optional} Complete to receive your copy of M. D. Anderson'sRoad Map to CancerPrevention.

(Continued from page 3)

85% are referred by their physician,
and the remainder come by selfreferral. Patients need not undergo
other therapy at M. D. Anderson to
have radiotherapy here.
Curative radiotherapy is the focus
of the division ·s efforts, although
paJliative therapy is p racticed. "We
support the idea th at p atients b eing
treated palliatively sh ould be treated
very close to home," said Dr. Cox.
David Bolling, deputy administrator of the division, reports that a
quarterly survey taken by an external
firm shows that patients give high
marks to the division 's work. In the
1996-1997 academic year, 97% of
patients reported overall satisfactio n
with their treatment. When asked
about the division's physicians,
therapists, nursing, environment, and
commitment/ teamwork, 96%-99%
reported satisfaction in each category.
Eighty-six percent said they would
definitely recommend creaunentat
M . D. Anderson. T he annual ratings
were based on postdischarge responses of 398 interviewees. Ratings at
the top of a 10-point scale (7-LO) were
identified as indicating satisfaction.
Education is also a part of the
division 's mission. Training in the
department at any time are about
16 residents and one or two fellows,
who come from across the country.
Trainees are likely to already be
familiar with faculty even before
coming to M. D. And erson through
textbooks or the 200-plus articles
produced annually by dep arunen tal
faculty.
The Division of Radiation Oncology includes the Dep artment of
Experimental Radiation Oncology,
the Department of Radiation Physics,
and the Department of Radiation
Oncology. The division faculty
in cludes 36 physicians and 21
scientists. •
FoR MORE INFORMATION, contact D r. Cox at
(713) 792-3411 or the M . D . Anderson

Name _ __ _ __ _ _ __ _ _ __ _ _ _ _ __ _ _ __ _ _ _

hiformation Line ai (800) 392-1611.

Address _ _ _ _ _ _ _ _ __ __ _ _ _ _ _ _ __ _ _ __ __

Those outside the United States should
call (713) 792-6161 to reach the
in:formation line.
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Cancer: Is it in the
Genes or in the Stars?

N

ow that hundreds of
hereditary disorders can
be detected even before
a baby is bom, the expression
"It :S- in the genes" has largely
replaced "Its in the stars" as a
common explanation for events.
It is true that physicians and
geneticists know d ramatically more
than they did a decade ago. 1onetheless, the meaning of phrases
like genetic code and genetic ,nutation
remain as remote in meaning to
most of us as the stars are distant.
But though their precise meaning
may be remote, their implications
are not.Just as a pregnant woman
is acutely aware of the consequences
to her unborn child of genes gone
wrong, so adults with genetic mutations know that their family's genetic
legacy can transfonn or even end
their lives.
In cancer care, physicians and
others are working to ensure that
genetic information not only identifies those at risk, but also leads to
better treatment and prevention.
Let's examine how cancers occur
and how to assess risk.

Ways Cancers Occur
Cancers occur in three ways. Most
cancers are not hereditary. These
are called sporadic cancers, and they
occur randomly. Familial cancers are
those that occur because of a genetic
predisposition to cancer in certain
fam ilies. These are also affected
by such nongenetic factors as environmental exposures or lifestyle.
Hereditary cancers are associated with
specific genetic mutations and are
governed by genetic principles of
inheritance. About 5%-10% of
cancers are inherited genetically.

Assessing Risk
What is your risk? Here are four
ways to assess it. Specially trained
professionals can also help.

Evaluate your family's medical
history. Look at first-degree relatives

High Stakes,
High Anxiety

(mother, fathe1~ siblings, children) ,
second-degree relations (grandparents, aunts, uncles, nieces, nephews, and grandchildren), and thirddegree relatives (cousins).

Counseling
is important in
determining if
genetic testing is
necessary, and it is
fu ndamental to successfuJly navigating the choppy waters
offear and anxiety associated wi th
testing. T he stakes are high, and
findings can bring conflict within the
family and worries about confidentiality, hiring discrimination, and
insurabilit-y outside the family.
Unfortunately, genetic test findings
don 'tforetell the future conclusively.
Identifying a gene mutation associated with a specific cancer doesn't
mean that cancer will inevitably occur:
it means risk is higher. Similarly, if no
cancer-associated mutation is found,
it doesn 't ensure a cancer-free life:
it means the person te.5ted has the
same risks as the general population.
In addition, sometimes scientists
discover genetic alterations whose
significance is unknown.
Science has crafted exquisite tools
for examining human genetics, and
highly trained physicians and counselors are prepared to help wield those
tools in cancer genetic screening.
It remains, however, a matter of
intensely personal choice whetheras well as how-to put those tools
to use.

Identify cause of death. If a relative
had cancer, try to find out how old
your relative was when he or she was
diagnosed, the location of the tumor,
and whether smoking was part of the
relativc's medical history.
Look for patterns that suggest
hereditary disease :

• Determine if the cancer occurred
in your relative earlier than is
typical.
• Find out if cancer has occurred
in more than one close relative.
• Enlist your physician's help in
determining whether there is a
pattern-cancer in both organs
in organs that are paired, a cancer
syndrome, or multiple primary
tumors in one person.
Ask your physician to help classify
your risk. If it is higher than normal,

your physician may suggest that you
gather more specific information on
your relatives or undergo genetic
testing and counseling.
lfyou need to gather more
information, obtain pathology
reports from the medical records of
yom relatives. These are statements
by a physician-scientist who studied
a sample of your relation 's tumor or
other tissue or blood in a laboratory.
Autopsy reports, hospital records, or
death certificates also provide clues.
For genetic testing and counseling, consult a cancer center or
hospital that is part of a university or
contact a genetics counselor. A list
of such counselors, which can be
searched by state, is p osted on the
World Wide Web site of the National
Cancer Institute (http://cancernet.
nci.nih.gov/ wwwprot/ genetic/
genesrch.html).

For more injonnation, contact
your physician or contac/; the
M. D. Anderson 111/ormation Line:

({) (800) 392-1611 within
the United States, or
({) (713) 792-6161 outside
the United States.
February 1998
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Genetic Findings Prompt
Cancer Survivor To Eled Surgery
by Alison Ruffin

Redacted
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Oinic Decodes
Genetic Risks,
Prevention Options

W

ith the knowledge that
about5%-10% of all
cancers can be attributed
to inherited genetic changes, more
people are becoming in terested in
learning whether they carry altered
genes that may place them at
higher risk of cancer.
To meet the need for genetic
risk assessment and co unseling,
The University of Texas M. D.
Anderson Cancer Center established the Human Clinical Cancer
Genetics Clin ic to study heritable
genetic m utation s that predispose

individuals to cancer. It focuses
on mutations that cause breast,
ovarian, endometrial, bowel, and
endocrine cancers. Genes related
to colon cancer susceptibility are
also a particular interest.
"This has the p o te ntial to revolutionize our approach to cancer,"
says Gordon Mills, M.D., wh o
e mphasizes the d ecision-making
role patients play in health care,
especially those who know the risks
associated with their genetic profile .
Dr. Mills chairs the Department
of Molecular Oncology and is
acting medical director of the
Breast and Ovarian Risk Assessment
Clinic at M. D. Anderson Cancer
Center.
"Risk counseling, genetics
counseling, and treatment counseling are important in communicating information to individuals,
allowing them to make appropriate
health care decisions," h e said.
Two other physicians, in addition to Dr. Mills, direct program
aspects. H eading the high-risk
bowel program is Patrick Lynch,
M.D., J.D., and heading the endocrine program is Robert Gagel, M.D.
A strong family h istory of cancer
is the primary reason for co nsultations, which may be re quested by
physicians for their patients or by
patients themselves.
"The basis of our p rogram is
cancer prevention," said Dr. Mills.
"Our goal is to help individuals

assess their risk for breast and
ovarian cancer so that they will
be able to consider the m erits of
potential prophylactic inter ventions. When prevention is not
possible, however, the next goal is
to initiate early detection an d
curative interventions."
The clinic Dr. Mills heads advises
individuals about risks related to
mutations in the genes BRCAl
and BRCA2 (the breast cancer 1
and breast cancer 2 genes). BRCAl
was first associate d with breast and
ovarian cancer occurrence abut six
years ago. Subsequently, scientists
successfully cloned BRCAJ a nd
BRCA.2, thus allowing study and
providing better unde rstanding
of their activity.

"This has the
potential to
revolutionize
our approach
to cancer:'
-Gonion MIiis, M.D.

About 10%- 30% of individ uals
with a mutation of the BRCAl gene
will eventually have ovarian cancer,
and about 40%-60% will have
breast cancer. Risk of colon and
p rostate cancer is elevated in these
individuals three to four tim es above
that for the normal po pulation. For
this reason, people with th ese gene
mutations should be counseled
a bout screening options for all
types of cancer.
Dr. Mills reminds those with
mutations that a n inhe 1-ited abnormality in one or more genes docs
not guarantee a cancer diagnosis,
but he advises, "Someone who
inherits an abnormality will essentially be at increase d risk for his or
her entire life."
Understanding inherited genetic
c hanges that can lead to can cer is
an impor tant step in developing
new, more e ffe ctive cancer prevention, d iagnostic, and treatmen t
strategies, according to Dr. Mills.

-Alison Ruffin
MD Anderson Onco Log / 7
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Genetic Tests Demand New Answers
Rebecca D. Pentz, Ph.D.
In the near future,
genetic testing will
be a standard part
of every oncologist's
practice. For the

counUJ we sterilized without consent
thousands of''feeble-minded" women
in an attempt to purify the American
germ plasm.
Properly info rming people about
genetic testing is thus a daunting task.
The consensus stateme nt published
in]AMA (1997;277:1467-74) suggests

physician, this

a two-stage approach. The first stage

advance will e ntail
not only bei ng
familiar with
genetics but also
informing p atients
adequately about new tests, includi n g
nonmedical risks and benefi ts.
Adequately informing patients about
diagnostic test findings and treatments
has never been easy. T he barriers are
substantial. Complex issues are difficult
Lo explain in lay terms. Some patients
don 't want to be informed; they want
physicians to make the decisions. Other
patients want information, but they may
be overwhelmed and unable to understand a physician 's explanations. Or a
quick decision about treatment may be
so important that a leisurely discussion
of ri.sks and benefits may actually increase the p atient's risk.
Genetic tests introduce n ew twists
to this laby1inth. Discovering a gene
mutation is information not just about
an individual but about an entire fam ily.
Add to this that genetic results are
probabilistic. Highly symbolic, genetic
results seem to reveal more of our
essence as individuals than our cholesterol count does. Furthermore, the
history of genetics includes the disturbing chapter on eugenics. Even in this

includes counseling about risks, benefits, and alternatives a nd is followed
by a waiting period for time to think.
Only after the waiting p eriod are
candidates asked whether they want
to proceed with testing.
The ethics con sultation service
recently reviewed a case exempluying
the complexity of genetic testing. IL
involved a wom an who had agreed to
give a blood sample for an epidemiological study. ln studying her sample,
the laboratory scientist detected an
abnormality tl1at had reproductive
implications. Should she be told even
though she had consented to give
blood for an entirely different study?
T he ethics team j udged she should
and devised a plan to tell her in the
most helpful manner.
Based on our experience and that o f
otl1er genetics centers, M. D. Anderson
has constructed an informed consentpart of our effort to inform adequately
-that includes many 1·elated issues as
well as this unusual circumstance. We
are not Pollyannaish about the difficulty of obtaining consent for genetic
testing, but using the staged approach
and guided by the informed consent
document, we think our process is
improving.

Clinical Ethicist
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